The ubiquitin-proteasome pathway plays a central role in the targeted destruction of cellular
proteins, including cell cycle regulatory proteins. Because these pathways are critical for the …

▪ Abstract Normal cellular functioning requires processing of proteins regulating cell cycle,
growth, and apoptosis. The ubiquitin-proteasome pathway (UBP) modulates intracellular …

Cellular homeostasis requires routine degradation of key regulatory proteins, including
tumor suppressor gene products, transcription factors, cell-cycle proteins and their inhibitors …

The 26S proteasome is a large intracellular adenosine 5′-triphosphate–dependent
protease that identifies and degrades proteins tagged for destruction by the ubiquitin system …

The proteasome is an intracellular enzyme complex that degrades ubiquitin-tagged proteins
and thereby regulates protein levels within the cell. Given this important role in maintaining …

The proteasome is responsible for the degradation of intracellular proteins, including several
involved in cell cycle control and the regulation of apoptosis. Preclinical studies have shown …

Abstract Bortezomib (formerly PS-341) has been the first proteasome inhibitor to enter
clinical trials in cancer patients. Based on results of preclinical studies showing that this …

Targeting intracellular protein turnover by inhibiting the ubiquitin–proteasome pathway as a
strategy for cancer therapy is a new addition to our chemotherapeutic armamentarium, and …

The ubiquitin-proteasome pathway is involved in intracellular protein turnover, and its
function is crucial to cellular homeostasis. First synthesized as probes of proteolytic …

VELCADE®(bortezomib, Millennium Pharmaceuticals, Inc., Cambridge, MA, and Johnson &
Johnson Pharmaceutical Research & Development, LLC, Raritan, NJ) is a first-in-class …